

(b)(6)

Regards

(b)(6)

(b)(6)

(b)(6)

On Mon, Jun 17, 2019 at 7:14 PM Peter Daszak <(b)(6)@ecohealthalliance.org> wrote:

Dear All,

(b)(5); (b)(5) - Deliberative Process Privilege

(b)(6)

We're planning to file on or around September 1st 2019 and at that point, or just before, we'll send documents out for your signatures. We'll then look for dates to set up our first Board meeting towards the end of the year, or early 2020.

(b)(5); (b)(5) - Deliberative Process Privilege

(b)(6)

For more information, please keep up to date via our newsletter that (b)(6) updates, our twitter account [@GlobalVirome](#), and the website [www.globalviromeproject.org](#) In the meantime... have a great summer, and I look forward to getting back to you all at the end of August.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

(b)(6)
Tel. +

Website: www.ecohealthalliance.org

Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

(b)(6)
--

www.ecohealthalliance.org

Page 4 of 4

(b)(6)

From: Peter Daszak
Sent: Thu, 28 Mar 2019 20:37:33 +0000
To: [REDACTED]@usaid.gov; [REDACTED]
Subject: Letter to the Board of Directors
Attachments: [REDACTED].docx
Importance: High

(b)(5); (b)(5) - Deliberative Process Privilege

(b)(6)

(b)(6)

[REDACTED] - I checked in with the lawyers re. the letter just to be safe, and they had an important suggestion for the letter that I think you should change out.

(b)(5); (b)(5) - Deliberative Process Privilege

I also removed the mention of the Executive Director earlier in the doc.

I realize this isn't the exact language you wanted, but it's safer for us at this sensitive point where we still have USAID funding being use for GVP related activities..

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

(b)(6)

Tel. [REDACTED]
Website: www.ecohealthalliance.org
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

Page 3 of 4

Withheld pursuant to exemption

(b)(5) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

Page 4 of 4

Withheld pursuant to exemption

(b)(5) ; (b)(6) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

Page 1 of 3

(b)(6)

I just wanted to check back in with you all and let you know where we are in the process of launching the GVP 501c3. Right now, the filing documents have been drafted, reviewed and revised by myself, [REDACTED] and are back with our *pro bono* lawyers for final versions to be prepared.

We're planning to file on or around September 1st 2019 and at that point, or just before, we'll send documents out for your signatures. We'll then look for dates to set up our first Board meeting towards the end of the year, or early 2020.

(b)(5); (b)(5) -
Deliberative
Process Privilege(b)(5); (b)(6);
(b)(5) -
Deliberative
Process Privilege

For more information, please keep up to date via our newsletter that [REDACTED] updates, our twitter account [@GlobalVirome](#), and the website www.globalviromeproject.org In the meantime... have a great summer, and I look forward to getting back to you all at the end of August.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

(b)(6)
Tel. [REDACTED]

Website: www.ecohealthalliance.org

Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

(b)(6)
[REDACTED]
EcoHealth Alliance

(b)(6)
460 West 34th Street – 17th floor

(b)(6)
New York, NY 10001

[REDACTED] (direct)

[REDACTED] (mobile)

1.212.380.4465 (fax)

www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.

(b)(6)

(b)(6)

(b)(6)

(b)(5); (b)(5) -
Deliberative
Process Privilege**From:****Sent:**

Wed, 27 Mar 2019 21:08:23 +0000

To:

Peter Daszak;

Subject:**Attachments:**(b)(5); (b)(5) -
Deliberative
Process Privilege

(b)(6)

All, for discussion and feedback during tomorrow's phone call

(b)(6)

(b)(6)

(b)(6)

Bureau for Global Health

U.S. Agency for International Development

Office:

Mobile:

(b)(6)

(b)(5); (b)(5) -
Deliberative
Process Privilege

Page 2 of 3

Withheld pursuant to exemption

(b)(5) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

Page 3 of 3

Withheld pursuant to exemption

(b)(5) ; (b)(6) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

(b)(6)

From: [REDACTED]
Sent: Tue, 18 Jun 2019 13:49:44 +0000
To: Peter Daszak
Subject: Re: Timeline for the GVP 501c3 filing

(b)(6)

:)

(b)(6)

[REDACTED]

U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division

(b)(6)

[REDACTED]

(b)(6)

(b)(6)

Desk: [REDACTED]
E-mail: [REDACTED]@usaid.gov

[REDACTED]

(b)(6)

On Mon, Jun 17, 2019 at 2:14 PM Peter Daszak [REDACTED]@ecohealthalliance.org> wrote:

Dear All,

(b)(6)

I just wanted to check back in with you all and let you know where we are in the process of launching the GVP 501c3. Right now, the filing documents have been drafted, reviewed and revised by myself, [REDACTED] and are back with our *pro bono* lawyers for final versions to be prepared.

(b)(5); (b)(5) -
Deliberative
Process Privilege

(b)(6)

For more information, please keep up to date via our newsletter that [redacted] updates, our twitter account [@GlobalVirome](#), and the website www.globalviromeproject.org In the meantime... have a great summer, and I look forward to getting back to you all at the end of August.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. + [redacted]

Website: www.ecohealthalliance.org

Twitter: [@PeterDaszak](#)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

(b)(6)
(b)(5); (b)(5) - Deliberative Process Privilege

From: Peter Daszak
Sent: Thu, 28 Mar 2019 01:26:49 +0000
To: [REDACTED]
Subject: [REDACTED]
Attachments: [REDACTED]

(b)(6)
(b)(5); (b)(5) - Deliberative Process Privilege

Here are a couple of [REDACTED]

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. + [REDACTED]
Website: www.ecohealthalliance.org
Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

(b)(6)
(b)(6)
(b)(6)
(b)(5); (b)(5) - Deliberative Process Privilege

From: [REDACTED]@usaid.gov]
Sent: Wednesday, March 27, 2019 5:08 PM
To: [REDACTED] Peter Daszak; [REDACTED]
Subject: [REDACTED]

(b)(6)
(b)(5); (b)(5) - Deliberative Process Privilege

All, for discussion and feedback during tomorrow's phone call - [REDACTED]

(b)(6)
(b)(6)

[REDACTED]

[REDACTED]

(b)(6)

(b)(6)

[Redacted]
Bureau for Global Health
U.S. Agency for International Development

Office:

Mobile:

(b)(6)

Page 3 of 4

Withheld pursuant to exemption

(b)(5) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

Page 4 of 4

Withheld pursuant to exemption

(b)(5) ; (b)(6) ; (b)(5) - Deliberative Process Privilege
of the Freedom of Information and Privacy Act

(b)(6)

(b)(6)

(b)(6)

From: [REDACTED]
Sent: Thu, 4 Apr 2019 12:36:29 +0000
To: [REDACTED]@metabiota.com
Subject: Fwd: [Welcome] Global Virome Project Board of Directors
Attachments: Letter: [REDACTED] 3.29.19.pdf, ATT00002.bin

Example letter attached.

Sent from my iPhone

Begin forwarded message:

(b)(6)

(b)(6)

From: GVP Team <info@globalvirome.org>
Date: April 3, 2019 at 8:02:21 PM EDT
To: [REDACTED]@gmail.com>
Subject: [Welcome] Global Virome Project Board of Directors

Dear [REDACTED]

We are pleased to welcome you as a member of the Board of Directors for the Global Virome Project. Please see your letter attached for full details, and please do not hesitate to contact us if you have any questions. We very much look forward to working with you.

Sincerely,
Global Virome Project Team



(b)(6)

March 29, 2019

(b)(6)

[Redacted]

The World Academy of Sciences & Nigerian Academy of Sciences,
Academy House, 8A Ransome Kuti Road,
University of Lagos,
Lagos, Nigeria.

(b)(6)

Dear [Redacted]

I am very pleased to welcome you as a member of the Board of Directors for the Global Virome Project (GVP). The transition of the GVP into a legal and operational reality is both exciting and daunting. The Board of Directors will be critical to ensuring the GVP's long term success. This transition has been a long time in the making. Over the past two years, a network of international partners has been actively guiding the evolution of the GVP from a "scientific" proposal towards an operational reality. This "Steering Committee" has provided a strong 10 year vision that frames the GVP's way forward in three phases – an initial "incubation period", a longer term "steady state", and the "post GVP" period.

The Incubation Period is the critical first phase that is intended to "validate the operational and scientific scalability" of the GVP; mobilize initial funding; and, build out the GVP organization. The incorporation of the GVP and the establishment of the Board of Directors are vital first steps towards building out the GVP's organizational structure. In parallel, the first steps have been taken to launch the "validation" phase in Thailand and China. Both countries are in the process of establishing their respective national Virome projects (the Thai Virome Project and the China Virome Project). Further, a series of scientific and operational working groups, overseen by the Steering Committee and composed of international scientific and legal experts, have provided a sound technical, scientific, and operational framework for the GVP's field activities. Together the Steering Committee and the Working Groups have well positioned the GVP for this next, exciting step.

With the legal launch of the GVP, the Board of Directors will be responsible for setting the GVP's overarching direction, championing stakeholder engagement, and providing financial oversight. In the coming months, the Board of Directors will be specifically responsible for approving membership to a Scientific Advisory Group and for providing oversight of the

operational work of the GVP's secretariat or "Hub". I will provide you with a more detailed introduction to the current organizational and strategic plan for the GVP in a separate communication.


As some of you may be aware, I will be retiring from my current position at USAID later this summer. I intend to use my time, as a voluntary member of the Board of Directors, to help accelerate the transition of the GVP into a fully-functioning organization. I strongly believe the GVP has the potential to transform how the global community understands, prepares for, and responds to future viral threats – and in the end will make the world a far safer place. I look forward to working with you to make this vision a reality.

In the coming weeks each of you will receive an email and packet drafted by the law offices of Tarter Krinsky & Drogin LLP including resolutions and bylaws for the new 501 (c) 3. You will be asked to sign and return the resolutions to formally accept your appointment to the Board.

At your convenience I can arrange a phone conversation to provide you additional information and answer any questions you might have.

(b)(6)

All the best,



GVP Core Team

(b)(6)

(b)(6)

From: (b)(6)
Sent: Tue, 30 Jan 2018 14:44:49 +0000
To: (b)(6)
Cc: Peter Daszak (b)(6)
Subject: Re: WDCM logo for GVP

(b)(6)

(b)(6)

Dear (b)(6) we are delighted at your show of support for GVP. We will add the WDCM logo immediately. I greatly appreciated your contributions to the meeting and believe the partnership with WDCM will prove very exciting. Again, thank you for taking the time from your busy schedule to come to Bangkok. It was great seeing you

(b)(6)

All my best

(b)(6)

(b)(6)

(b)(6)

(b)(6)

(b)(6)

U.S. Agency for International Development
Office: (b)(6)
Mobile: (b)(6)

(b)(6)

On Jan 30, 2018, at 9:03 PM, (b)(6) <[@im.ac.cn](mailto:(b)(6)@im.ac.cn)> wrote:

Dear (b)(6) Peter, (b)(6)

I think that you arranged a very successful meeting for GVP, all participants think the GVP is important.
And I learned a lot from the workshop.

I believe that our Chinese side can make our great contributions for the development of GVP database system and data portal by the supports from China CDC and CAS.

By the way, in the workshop I saw a PPT for the organizational partners, I put it in the attachment.

May I have WDCM also in the list? I put WDCM logo in the attachment. WDCM will be happy to make our contributions to GVP for data standard, database development, data portal and training courses.

Thank you for your invitation for this workshop, and hope to see you all soon in somewhere next time, maybe in Beijing.

Best regards,

(b)(6)



<IMG_20180129_152852.jpg>

<WDCM logo.jpg>

(b)(6)
(b)(6)
(b)(6)
From: [REDACTED]
Sent: Tue, 4 Apr 2017 22:15:41 +0000
To: [REDACTED]
Cc: [REDACTED]@hku.hk; Peter Daszak [REDACTED]
Subject: Re: URGENT Question

(b)(6)
OK but dont mind if less auyhorships

(b)(6)
发自我的 iPhone [REDACTED]

在 2017年4月5日, 上午4:36, [REDACTED]<[REDACTED]@usaid.gov> 写道 :

(b)(6)
All, we have been contacted by the Financial Times to write an OP-Ed for GVP. Thats the good news. The bad is they want it by tomorrow (April 5) by COB London time. [REDACTED] and I are doing a quick write up - but if possible we would like to include you all as authors. Wed dont know whether they will accept more than two names, but if so it would be great to have you as part of the fun. If you give an ok it will be sight unseen for you; we will need to submit before you can review. We dont expect to say anything beyond our normal pitch: threats are increasing, we are not prepared, we need to be more proactive, the virome is ours to discover and and new world order is in play :)

And again, they might limit authorship so dont be disappointed.

(b)(6)
Let us know when you can . thanks

(b)(6)
(b)(6)
[REDACTED]
Bureau for Global Health
U.S. Agency for International Development

Office: [REDACTED]
Mobile: [REDACTED]

(b)(6)
(b)(6)
From: [REDACTED]
Sent: Wed, 24 Jan 2018 14:06:30 +0000
To: [REDACTED]
Subject: Re: PMAC 2018 - Kick Off Plenary - Plenary 0

(b)(6)
Thanks [REDACTED] I wasn't aware of your unavailability but can more than appreciate that you have many competing demands on you in your new position. That said, we are eager to our partnership with you on GVP in the coming year. We will look for opportunities for begin translating GVP into a reality with your support.

(b)(6)
(b)(6)
(b)(6)
All my best
[REDACTED]

(b)(6)
On Tue, Jan 23, 2018 at 11:46 PM, [REDACTED] <[REDACTED]@im.ac.cn> wrote:

(b)(6)
Dear [REDACTED]

(b)(6)
I am sorry for not being able to attend yhis meeting due to my heavy duties in China CDC. I thought I wrote to you before. Sorry for this if I did not write you earlier.

(b)(6)
All the best
[REDACTED]

(b)(6)
发自我的 iPhone [REDACTED]

(b)(6)
在 2018年1月24日, 上午5:34, [REDACTED] <[REDACTED]@usaid.gov> 写道 :

(b)(6)
Dear [REDACTED] first, let me thank each of you for agreeing to participate in the "kick off" plenary for PMAC 2018 - Plenary Session 0 - "Vision 2100: Re-imagining the End Game for the End of the Pandemic Era". Given your collective backgrounds AND personalities this session should prove to be quite an event. Our session is scheduled for Thursday, February 1, 11:00 - 12:30, following the Opening Session with Her Royal Highness. The Plenary will open with a 20 minute "scene setting" Keynote by [REDACTED] - who will provide an "exploration of trends and dynamics that make the 21st century" a period of extraordinary risk from zoonotic diseases and antimicrobial resistance. Following [REDACTED] presentation I will ask each of you to provide a crisp (up to) 5 minute statement that can be partly a reflection on the points highlighted by [REDACTED] and your own perspectives on the "challenges and opportunities" we face. (No power points required - but if you wish to use a slide or two let me know and we can make the necessary arrangements). Your comments should be intended to challenge the audience to think "out of the box" about the problems and the solutions - and set the stage for the rest of the conference for "innovative and creative" thinking".

(b)(6)
A core theme across the conference is "multi-sectoralism" - how both the problems and the solutions span multiple sectors - and how we as a global community need to "break down" the silos that have isolated our human and animal health sectors, our environmental sectors etc, as well as our private and public sectors. After your opening comments I will ask several questions (ones that I will base on [REDACTED] presentation - so [REDACTED] as soon as you have a copy to share that would be great). I will discuss these question with you in advance and modify them based on your input. After, I will open it up to the audience to submit written questions which I will read.

Note, that the recipient of this years PMAC Award is "The Human Genome Project. This is an especially timely award as it highlights how the power of big data can transform medical research

and global health. It would be important and appropriate to consider how big data in other aspects of science and public health can be similarly transformative as we face the future

The session is intended to be informative but also lively, so draw on your familiarity with each other to create an intimate exchange.

For your background reading I am attaching a brief 2 page overview of the Plenary. If you have any questions, please do not hesitate to get in touch

It would be good to meet prior to our session to finalize our planning. Can everyone share their planned arrival and we can then try to coordinate a meeting?

Looking forward to seeing you all in Bangkok.

All my best

--

Bureau for Global Health
U.S. Agency for International Development

Office:

Mobile:

<PMAC 2018.Plenary 0.9.02.17.docx>

Bureau for Global Health
U.S. Agency for International Development

Office:

Mobile:

(b)(6)
(b)(6)
(b)(6)
From: [REDACTED]
Sent: Tue, 20 Feb 2018 09:02:27 -0800
To: [REDACTED]@im.ac.cn
Subject: [REDACTED] Re: Final proofs from Science

(b)(6)
Thanks for your email!

(b)(6)
(b)(6)
[REDACTED]
In general, for any inquiries related to the Emerging Threats Division or the Global Virome Project, please reach out to [REDACTED]@usaid.gov with a cc to his scheduler, [REDACTED]@usaid.gov, as appropriate. (b)(6)

(b)(6)
For any GH Research questions, please reach out to [REDACTED] at [REDACTED]@usaid.gov.

For more specific items, please see additional contacts below who can either answer any questions or direct you to the appropriate person.

(b)(6)
Contacts:

- Emerging Threats Division (ETD) and Emerging Pandemic Threats 2 (EPT-2) Program inquiries: [REDACTED]@usaid.gov
 - ETD Taskers/Action Items: [REDACTED]@usaid.gov & [REDACTED]@usaid.gov
 - As a reminder:
 - ETD/EPT Budget Requests: [REDACTED]@usaid.gov
 - GHSA Requests: [REDACTED]@usaid.gov, [REDACTED]@usaid.gov and [REDACTED]@usaid.gov
- Global Virome Project (GVP): [REDACTED]@usaid.gov
- GH Research Group: [REDACTED]@usaid.gov
 - GH Reports to Congress & GH Research Strategy: [REDACTED]@usaid.gov
 - GH Research Communications: [REDACTED]@usaid.gov
 - GH Research Data Visualization: [REDACTED]@usaid.gov
 - Authorship/Publication Policy: [REDACTED]@usaid.gov
 - PHuNdamentals: [REDACTED]@usaid.gov
 - USAID R&D Council (GH Topics): [REDACTED]@usaid.gov & [REDACTED]@usaid.gov
- Health Research Information Tracking System (HRIT): [REDACTED]@usaid.gov
- Global Health Science & Practice (GHSP): [REDACTED]@usaid.gov & [REDACTED]@usaid.gov

- PREDICT-2 Project: [redacted]@usaid.gov)
- NASEM Forum on Microbial Threats: [redacted]@usaid.gov) & [redacted]
[redacted]@usaid.gov)
- PLGHA
 - ID: [redacted]@usaid.gov)
 - ETD: [redacted]@usaid.gov)
- FEVS Group: Please use the group list: fevs.ghactiongroup@usaid.gov
- Building a Leadership Culture & Performance Management: [redacted]
[redacted]@usaid.gov)

[redacted]

Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: [redacted]
Cell: [redacted]
E-mail: [redacted]@usaid.gov

Page 1 of 2

(b)(5); (b)(5) -
Deliberative
Process Privilege

[Redacted]

Thanks,

[Redacted]

[Redacted]

Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: [Redacted]

Cell: [Redacted]

E-mail: [Redacted]@usa.gov

(b)(6)
(b)(6)
From: [REDACTED]
Sent: Tue, 21 Feb 2017 18:57:19 +0000
To: [REDACTED]
Subject: Re: Bellagio follow-up meeting 2018

(b)(6)
Hi [REDACTED]

(b)(6)
I just realized that I didn't follow up, my apologies! I checked with [REDACTED] and we do not currently have the dates set for the next meeting and need to have further conversations. He noted that PMAC would be Jan 29- Feb. 2018, though, and that we'll need to consider that in our planning.

(b)(6)
Best,
[REDACTED]

(b)(6)
(b)(6)
(b)(6)
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

(b)(6)
Desk: [REDACTED]
Cell: [REDACTED]
E-mail: [REDACTED]@usaid.gov

(b)(6)
On Thu, Feb 16, 2017 at 10:42 PM, [REDACTED]@usaid.gov> wrote:

(b)(6)
Hi [REDACTED]

(b)(6)
As far as I know, we have not actually scheduled anything and we might have some flexibility. I'll check with [REDACTED] and verify that and let you know.

(b)(6)
Best,
[REDACTED]

(b)(6)
Sent from my iPhone

(b)(6)
(b)(6)
On Feb 16, 2017, at 8:07 PM, [REDACTED]@im.ac.cn> wrote:

(b)(6)
Dear [REDACTED]

(b)(6)
I remembered [REDACTED] planned the follow-up meeting in the week of 8-14 Jan 2018. Have you got dates fixed yet as I need to plan another meeting that week

(b)(6)
Best
[REDACTED]

(b)(6)

发自我的 iPhone [REDACTED]

(b)(6)

在 2017年2月15日, 上午6:21,
写道 :

[@usaid.gov](#)

Dear Colleagues,

As I mentioned in my email to the larger group, we would like to arrange for a monthly call among the thematic area co-leads (as well as the additional core group members) in advance of the May 1st deadline. While we hope that the working groups will be in communication, as needed, we hope that these calls will enable us to identify any roadblocks and keep one another updated moving forward.

We would like to propose an early March time for the first call. We realize that with time differences, it may be hard to get everyone, but we hope to have at least 1 rep from each thematic area.

Please let me know if you have a scheduler or assistant who should be included in the emails and we will likely send out a doodle poll soon to identify a day/time.

Sincerely,

[REDACTED]

Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

(b)(6)

(b)(6)

(b)(6)

(b)(6)

Desk: [REDACTED]

Cell: [REDACTED]

E-mail: [REDACTED]

[@usaid.gov](#)

From: [REDACTED]
Sent: Thu, 8 Feb 2018 00:30:50 +0000
To: [REDACTED]@metabiota.com

[REDACTED]@ecohealthalliance.org; [REDACTED]@usaid.gov; [REDACTED]@ecohealthalliance.org; [REDACTED]@ecohealthalliance.org; [REDACTED]@ecohealthalliance.org; [REDACTED]@ecohealthalliance.org; [REDACTED]@ecohealthalliance.org; [REDACTED]@gisaid.org; [REDACTED]; [REDACTED]
[REDACTED]@who.int; [REDACTED]@mahidol.edu; [REDACTED]
[REDACTED]@graduateinstitute.edu; [REDACTED]@georgetown.edu; [REDACTED]
[REDACTED]@fao.org; [REDACTED]@fao.org; [REDACTED]
[REDACTED]@fondation-merieuxusa.org; [REDACTED]
[REDACTED]@bcg.com; [REDACTED]@bcg.com; [REDACTED]@usaid.gov; [REDACTED]@pan
[REDACTED].org; [REDACTED]@mahidol.edu; [REDACTED]@mahidol.edu; [REDACTED]@mahidol.edu; [REDACTED]
[REDACTED]@mahidol.ac.th; [REDACTED]@mahidol.edu; [REDACTED]@ecohealthalliance.org; parntep@mahidol
ac.th; [REDACTED]'@pasteur.fr'; [REDACTED]
[REDACTED]@fondation-
[REDACTED].rg; [REDACTED]@columbia.edu; [REDACTED]@usaid.gov; [REDACTED]@niaid.nih.gov; [REDACTED]@duke
[REDACTED].edu.sg; [REDACTED]@cumc.columbia.edu; [REDACTED]@im[REDACTED]@metabiota.com; [REDACTED]@ecohealthallia
nce.org; [REDACTED]@ucsf.edu; [REDACTED]@cdts[REDACTED]
[REDACTED]@im.ac.; [REDACTED]@ufl.edu; [REDACTED]@childrens.harvard.edu; [REDACTED]
[REDACTED]@phfi.org; [REDACTED]@gmail.com; [REDACTED]@cepi.net; [REDACTED]@wellco
me.ac.uk; [REDACTED]@fao.org; [REDACTED]@merck.com; [REDACTED]@who.int; [REDACTED]

Cc: [redacted]@bcg.com; [redacted]
Subject: 答复: GVP PMAC side meeting - presentation slides

Dear

Thank you for arranging the nice GVP workshop. We all learned a lot.

I have sent you my ppt file.

And looking forward for the future cooperation.

Best regards,

Institute of Microbiology, Chinese Academy of Sciences
NO.1-3 West Beichen Road, Chaoyang District,
Beijing 100101, P. R. China
Tel: [REDACTED]
FAX: +86-10-64807426

(b)(6)



One Health Institute
School of Veterinary Medicine
University of California, Davis

(b)(6)
(b)(6)
(b)(6)
From: [REDACTED]
Sent: Tue, 31 Jan 2017 16:40:27 +0000
To: [REDACTED]
Cc: [REDACTED] Peter Daszak [REDACTED]
Subject: Re: Request - Remarks at the GVP Beijing Meeting

(b)(6)
Thank you!

[REDACTED]
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

(b)(6)
(b)(6)
(b)(6)
(b)(6)
Desk: [REDACTED]
Cell: [REDACTED]
E-mail: [REDACTED]@usaid.gov

(b)(6)
On Tue, Jan 31, 2017 at 10:59 AM, [REDACTED]@im.ac.cn> wrote:

(b)(6)
Yes

(b)(6)
Looking forward to seeing you in Beijing

[REDACTED]
发自我的 iPhone [REDACTED]

(b)(6)
在 2017年1月31日, 上午5:32, [REDACTED]@usaid.gov> 写道 :

Hi [REDACTED]

I hope all is well on your end and I look forward to seeing you in Beijing!

[REDACTED]

(b)(5); (b)(5) -
Deliberative
Process Privilege

(b)(6)

Please let me know if you have any concerns and thank you in advance!

(b)(6)

Thanks,

(b)(6)

(b)(6)

(b)(6)

(b)(5); (b)(5)
Deliberative
Process Privilege

Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: [REDACTED]

Cell: [REDACTED]

E-mail: [REDACTED]@usaid.gov

[REDACTED]

(b)(6)

(b)(6)

(b)(6)

(b)(6)

From: [REDACTED]
Sent: Wed, 3 Oct 2018 13:51:31 +0000
To: [REDACTED]
Peter Daszak [REDACTED]
[REDACTED]
Cc: [REDACTED]@ecohealthalliance.org
Subject: Re: Action Requested - GVP Selection Committee Membership

Dear Colleagues,

(b)(6)

Just a quick reminder of the action requested below. Please let me know by COB Friday if you would like to participate in the GVP Selection Committee and/or if you have any suggested nominees to participate. If you aren't interested, no need to respond!

Best,

(b)(6)

[REDACTED]

U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division

(b)(6)

(b)(6)

(b)(6)

(b)(6)

Desk: [REDACTED]
Cell: [REDACTED]
E-mail: [REDACTED]@usaid.gov

(b)(6)

[REDACTED]

(b)(6)

On Fri, Sep 28, 2018 at 10:35 AM [REDACTED]@usaid.gov wrote:
Dear GVP Steering Committee Members,

We hope that you are all doing well!

We wanted to follow up on the next steps for GVP governance discussed during the last GVP Steering Committee meeting in DC. One of the proposed next steps was to identify a Selection Committee who will be tasked with selecting the Board of Directors (BoD) for the GVP.

The decision was that the current Steering Committee members would be asked A) if they would like to participate in the Selection Committee, and B) if there are others whom they would recommend to participate. The goal is to ensure that we have a diverse set of perspectives in order to ensure a high quality BoD.

Action Requested (Please respond by close of business on **Friday, October 5th**):

- Please respond to this email (ideally, please do not "reply all") with your interest in participating in the GVP Selection Committee. If you do not respond, we will assume you are not interested in participating.
- If you have others who you would recommend for the Selection Committee, please respond with those names and any contact information you have (email, institution, etc.). If you have already confirmed the individual's interest, please include that in your message.

Once we have received all the nominations and compiled them, we'll reach back out regarding next steps.

Have a wonderful weekend,

U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division

Desk: [REDACTED]
Cell: [REDACTED]
E-mail: [REDACTED]@usaid.gov